Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study

Authors
Category Primary study
JournalJournal of Hepatology
Year 2022
This article has no abstract
Epistemonikos ID: c4653446c1fa4395d561a8cb536b2accd08066e3
First added on: Feb 14, 2025